Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

Core Points - Emergent BioSolutions Inc. has been awarded a contract modification by BARDA valued at $41.9 million for the development and scale-up of Ebanga™ [1][2] - The existing contract is a 10-year agreement with a total value of approximately $704 million, which includes advanced development and procurement options [2][3] - The contract aims to support the ongoing scale-up program for Ebanga™, a treatment for Ebola virus disease [1][2] Company Overview - Emergent BioSolutions focuses on providing critical medical countermeasures and has a mission to protect and enhance life through vaccines and therapeutics [9] - The company has been active for 25 years in defending against public health threats and aims to protect or enhance 1 billion lives by 2030 [10] Product Information - Ebanga™ is a human monoclonal antibody indicated for treating infections caused by Zaire ebolavirus in various patient demographics [5] - The efficacy of Ebanga™ is not established for other Ebolavirus species or Marburgvirus genera, and its clinical benefit may be affected by changes in viral resistance or virulence [5] Contract Details - The contract includes activities such as technology transfer for manufacturing scale-up, submission of a supplemental Biologics License Application to the FDA, and completion of stability studies [3] - The contract modification aligns with Emergent's planned program performance and critical path for the development of Ebanga™ [2]